# Talzenna (talazoparib tosylate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/talazoparib

> The FDA approved Talzenna (talazoparib tosylate), sponsored by PFIZER INC (PFE), on March 7, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Talzenna (talazoparib tosylate) |
| Codes |  |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications | Advanced Malignancies |
| Modality |  |
| FDA designations | priority review |

## Timeline

### October 16, 2018: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211651 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20181016, review_priority PRIORITY; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211651%22

### March 9, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211651 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20200309, review_priority STANDARD; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211651%22

### October 22, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211651 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20201022, review_priority STANDARD; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211651%22

### September 9, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211651 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20210909, review_priority STANDARD; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211651%22

### June 20, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211651 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20230620, review_priority PRIORITY; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211651%22

### March 7, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA217439 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20240307, review_priority STANDARD; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217439%22

### May 21, 2025: FDA advisory committee meeting

- Status: completed, negative. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "On the afternoon of May 21, 2025, the Committee will discuss supplemental new drug application (sNDA) 211651/S-013, for TALZENNA (talazoparib) capsules, submitted by Pfizer Inc. The proposed indication (use) is in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC)." https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025
- FDA advisory committee calendar: "VOTE: Are the results from TALAPRO-2 sufficient to conclude a favorable benefit-risk profile for adding talazoparib to enzalutamide in patients with non-homologous recombination repair mutated (non-HRRm) metastatic castration-resistant prostate cancer (mCRPC)? Vote Result: Yes: 0 No: 8 Abstain: 0" https://www.fda.gov/media/187747/download

### June 12, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA217439 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20250612, review_priority PRIORITY; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217439%22
- openFDA Drugs@FDA: "NDA211651 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20250612, review_priority PRIORITY; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211651%22

### October 26, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA217439 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20261026, review_priority PRIORITY; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217439%22
- openFDA Drugs@FDA: "NDA211651 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20261026, review_priority PRIORITY; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211651%22

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Advanced Malignancies; NSCLC; Ovarian Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05059522 (Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT05059522

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Advanced Malignancies; NSCLC; Ovarian Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05059522 (Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT05059522

## Same indication

- [BAT1706](https://sec-api.dev/pdufa/bat1706) (ONC)

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/talazoparib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Talzenna (talazoparib tosylate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/talazoparib

```bibtex
@misc{secapidev_pdufa_talazoparib_20261116,
  title        = {Talzenna (talazoparib tosylate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/talazoparib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_talazoparib_20261116","title":"Talzenna (talazoparib tosylate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/talazoparib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
